N/A N=30 Randomized Treatment

Efficacy of Dry Needling in Plantar Fasciitis

Fasciitis, Plantar

Bottom Line

View on ClinicalTrials.gov: NCT02467465 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2020

Primary outcome: Primary: Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View. — 5.3; 4.7 millimeters

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Physical therapy modalities (Other); Invasive Physical therapy modalities (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Universidad Complutense de Madrid
Primary completion: Apr 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View.	4.4; 3.9	0.466
PRIMARY Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View.	4.4; 3.9	0.466
PRIMARY Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View.	4.4; 3.9	0.466
PRIMARY Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View.	4.4; 3.9	0.466
SECONDARY Pain Assessment in the Affected Heel, by Visual Analog Scale.	0; 0	0.066
SECONDARY Pain Assessment in the Affected Heel, by Visual Analog Scale.	0; 0	0.066
SECONDARY Pain Assessment in the Affected Heel, by Visual Analog Scale.	0; 0	0.066
SECONDARY Pain Assessment in the Affected Heel, by Visual Analog Scale.	0; 0	0.066
SECONDARY Pain Assessment in the Affected Heel After Long Periods of Rest, by Visual Analog Scale.	0; 0	0.487
SECONDARY Pain Assessment in the Affected Heel After Long Periods of Rest, by Visual Analog Scale.	0; 0	0.487
SECONDARY Pain Assessment in the Affected Heel After Long Periods of Rest, by Visual Analog Scale.	0; 0	0.487
SECONDARY Pain Assessment in the Affected Heel After Long Periods of Rest, by Visual Analog Scale.	0; 0	0.487
SECONDARY Goniometric Assessment of Joint Range of Motion Ankle Dorsiflexion With Knee Extended.	104; 108	0.755
SECONDARY Goniometric Assessment of Joint Range of Motion Ankle Dorsiflexion With Knee Extended.	104; 108	0.755
SECONDARY Goniometric Assessment of Joint Range of Motion Ankle Dorsiflexion With Knee Extened.	100; 104	0.387
SECONDARY Goniometric Assessment of Joint Range of Motion Ankle Dorsiflexion With Knee Extended.	104; 108	0.755
SECONDARY Goniometric Assessment of Joint Range of Motion Ankle Dorsiflexion With Knee Flexed.	110; 110	0.279
SECONDARY Goniometric Assessment of Joint Range of Motion Ankle Dorsiflexion With Knee Flexed.	110; 110	0.279
SECONDARY Goniometric Assessment of Joint Range of Motion Ankle Dorsiflexion With Knee Flexed.	110; 110	0.279
SECONDARY Goniometric Assessment of Joint Range of Motion Ankle Dorsiflexion With Knee Flexed.	110; 110	0.279

Summary

The plantar fasciitis (PF) is the most common cause of pain on the underside of the heel. About 10% to 20% of the population suffer once during their lifetime. PF concept began to describe at the end of XX century through the discovery of new clinical and histopathological signs of the plantar fascia. The difficulty of diagnosis, understanding and treatment of PF require us to develop new treatment avenues to improve the approach and the understanding of it. Dry needling (DN) as a treatment of myofascial pain syndrome (MPS) and myofascial trigger points (MTP) of muscle associated with the pathology, it may be a good treatment strategy, as demonstrated in the treatment of MPS in other body regions such as the neck, shoulder or the lumbar spine.

Eligibility Criteria

Inclusion Criteria

Ultrasonographic study in which a proximal thickened affected plantar fascia is observed -greater than or equal to 4 mm.
Pain fell to the first steps in the morning.
Pain with palpation at the insertion of the medial calcaneal tubercle, above 5, in a 10-point VAS.
Pathology time evolution of greater than or equal to 4 weeks.
Age of patients over 18 years.
Acceptance by the patient to participate in the study, having signed the informed consent.

Exclusion Criteria

Presence of neoplastic disease.
Presence of neurological, sensory, orthopedic and / or surgical alterations.
The patient is already doing treatment of physical medicine and rehabilitation.
Be subjected to antiplatelet drug therapy.
Fear of needles (needle phobia).
Difficulty for the patient to understand the instructions to be followed during the study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02467465). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.